Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial
Authors:
Top Cited Papers
Open Access
- 1 March 2021
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 21 (3) , 354-365
Abstract
No abstract availableKeywords
Funding Information
- South African Medical Research Council
- Bill and Melinda Gates Foundation
This publication has 19 references indexed in Scilit:
- Considerations for biomarker-targeted intervention strategies for tuberculosis disease preventionTuberculosis, 2018
- Diagnostic performance of an optimized transcriptomic signature of risk of tuberculosis in cryopreserved peripheral blood mononuclear cellsTuberculosis, 2018
- Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis diseasePLOS Pathogens, 2017
- A novel blood test for tuberculosis prevention and treatmentSouth African Medical Journal, 2016
- Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosisEuropean Respiratory Journal, 2016
- A blood RNA signature for tuberculosis disease risk: a prospective cohort studyThe Lancet, 2016
- National tuberculosis prevalence surveys in Asia, 1990–2012: an overview of results and lessons learnedTropical Medicine & International Health, 2015
- Is Passive Diagnosis Enough?American Journal of Respiratory and Critical Care Medicine, 2013
- Three Months of Rifapentine and Isoniazid for Latent Tuberculosis InfectionNew England Journal of Medicine, 2011
- Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic ReviewPLOS ONE, 2011